The identification of psychotic features in persons with mental retardation is challenging as the presence of hallucinations and delusions are disclosed through verbal self-report. In persons with mental retardation, self-report data is limited in utility because of the neuropsychological impairments that are uniformly reflected in limited communication and linguistic functions. Two major areas of misdiagnosis occur when interpreting reported hallucinations and delusions. First, the patient with mental retardation may experience a true hallucination or delusion, the content of which is very bizarre or disjointed, leading clinicians to identify schizophrenia or psychotic disorders when the condition is far less severe. Second, the patients's reported phenomena are not true hallucinations or delusions, but are instead self-talk, imaginary friends, or fantasy, similar to normal coping mechanisms of children. Mental health professionals must give priority to vegetative symptoms and mood states during the diagnostic assessment. It is also recommended that multiple sources of caregiver data be collected and that psychological projective testing be used as part of the evaluation process. Further, a false-positive strategy should be adopted when initiating treatment, favoring underdiagnosis of psychotic disorders.

Download full-text PDF

Source
http://dx.doi.org/10.1053/SCNP00100122DOI Listing

Publication Analysis

Top Keywords

hallucinations delusions
16
mental retardation
16
persons mental
12
psychotic disorders
8
mental
5
misdiagnosis hallucinations
4
delusions
4
delusions persons
4
retardation
4
retardation neurodevelopmental
4

Similar Publications

Background: Paliperidone is a second-generation antipsychotic and the main active metabolite of risperidone, formulated to provide consistent therapeutic effects through an extended-release system, designed to provide consistent therapeutic effects through an extended-release formulation. While commonly used in clinical practice, switching from risperidone to paliperidone, particularly during valproate therapy, can pose challenges due to potential pharmacokinetic interactions that may increase the risk of extrapyramidal symptoms (EPS). Despite clinical observations suggesting these interactions, case reports documenting such adverse effects are scarce.

View Article and Find Full Text PDF

Exploring delusional themes and other symptoms in first episode psychosis: A network analysis over two timepoints.

Psychiatry Res

January 2025

Department of Psychiatry, Faculty of Medicine and Health Sciences, McGill University, 1033 Pine Avenue West, Montreal, QC, , H3A 1A1, Canada; Prevention and Early Intervention Program for Psychosis, Douglas Mental Health University Institute, 6875 Blvd. LaSalle, Montreal, QC, , H4H 1R3, Canada. Electronic address:

Delusions are a defining feature of psychosis and play an important role in the conceptualization and diagnosis of psychotic disorders; however, the particular role that different delusions play in the prognosis of these disorders is not well understood. This study explored relationships between delusions and other symptoms in 674 first episode psychosis (FEP) individuals by comparing symptom networks between baseline and 12 months after intake to an early intervention service. Specifically, we (1) estimated regularized partial correlation networks at baseline and month 12, (2) identified the most central symptoms in each network, (3) identified clusters of highly connected symptoms, and (4) compared networks to examine changes in structure and connectivity.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Division of Neurology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

Background: We explored the relationship of neuropsychiatric symptoms (assesses by NPI) and Alzheimer disease pathophysiology from blood AB42/40, GFAB, NFL, and pTau181. We also investigated if age and cognition were related to these neuropsychiatric symptoms.

Method: 222 subjects included 96 dementia, 66 MCI, and 60 normal controls (NC).

View Article and Find Full Text PDF

Background: Neuropsychiatric symptoms (NPS) constitute a major challenge for patients with Alzheimer's disease (AD). We have recently demonstrated that in AD, overall NPS burden is significantly associated with patient function. However, few studies have examined the relationship between specific symptom clusters with neurological biomarkers.

View Article and Find Full Text PDF

Background: We present Phase 1 trial data using the Neuropsychiatric Inventory ("NPI") domains, NPI-delusions and NPI-hallucinations as symptoms of psychosis in participants with Alzheimer's ("AD") receiving IGC-AD1, a combination of low concentration delta 9-tetrahydrocannabinol ("THC") and melatonin. Cannabis use is considered an established risk factor for psychosis in young people. Psychosis is prevalent in AD patients, with around 50% experiencing it, generating safety concerns regarding the use of THC in these patients.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!